Skip to main content
Erschienen in: Herz 4/2015

01.06.2015 | e-Herz: Original article

Effects of renal sympathetic denervation and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy

Comparison in spontaneously hypertensive rats

verfasst von: X. Ding, X. Xu, Y. Yan, X. Song, S. Liu, G. Wang, D. Su, Q. Jing, Y. Qin

Erschienen in: Herz | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The aim of this study was to investigate whether renal sympathetic denervation (RSD) is more effective on myocardial hypertrophy than the angiotensin-converting enzyme inhibitor (ACEI) perindopril in spontaneously hypertensive rats (SHRs).

Methods

After bilateral renal denervation blood pressure (BP) was measured every 10 days. On day 50 the heart was (histo)pathologically examined. The ventricular weight to body weight ratios (VW/BW), myocardial diameter and collagen volume fraction (CVF) were calculated, and cardiac hypertrophy marker genes were analyzed by RT-PCR.

Results

At the baseline evaluation all groups had comparable BP. After treatment the BP of the RSD group was significantly reduced (p < 0.05). The BP of the RSD group was lower than that of the perindopril group on days 10, 20 and 30th (p < 0.05) but on day 50 systolic BP of the RSD group was significantly higher (p < 0.05) whereas there were no significant differences in diastolic BP. The VW/BW decreased in the RSD group, whereas the value did not change significantly in the perindopril group. The myocardial diameter of the left ventricular cardiomyocytes was also significantly lower in the RSD group and stayed the same in the perindopril group. Collagen volume fraction (CVF) in the RSD group was significantly lower than in the perindopril group (p < 0.05). Significant changes in the expression levels of NPPA, MYH7, and MYH6 (P < 0.05) were observed in the RD-SHR groups (p < 0.05). There was a significant difference in the expression level of MYH6 (p < 0.05) between the RSD group and the perindopril group but the expression levels of NPPA and MYH7 were not significantly different.

Conclusion

In this study, RSD had a significant antihypertensive effect and inhibited hypertensive-induced cardiac hypertrophy in SHRs and showed advantages compared with ACEI in decreasing BP in the early stage and in inhibiting myocardial fibrosis.
Literatur
1.
2.
Zurück zum Zitat Agabiti-Rosei E, Muiesan ML (2002) Left ventricular hypertrophy and heart failure in women. J Hypertens Suppl 20:S34–S38PubMed Agabiti-Rosei E, Muiesan ML (2002) Left ventricular hypertrophy and heart failure in women. J Hypertens Suppl 20:S34–S38PubMed
3.
Zurück zum Zitat Ruilope LM, Schmieder RE (2008) Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens 21:500–508PubMedCrossRef Ruilope LM, Schmieder RE (2008) Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens 21:500–508PubMedCrossRef
4.
Zurück zum Zitat Lindholm LH, Carlberg B, Samuelsson O (2005) Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545–1553PubMedCrossRef Lindholm LH, Carlberg B, Samuelsson O (2005) Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545–1553PubMedCrossRef
5.
Zurück zum Zitat Williams B, Lacy PS, Thom SM et al (2006) Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113:1213–1225PubMedCrossRef Williams B, Lacy PS, Thom SM et al (2006) Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113:1213–1225PubMedCrossRef
6.
Zurück zum Zitat Yang CM, Kandaswamy V, Young D, Sen S (1997) Changes in collagen phenotypes during progression and regression of cardiac hypertrophy. Cardiovasc Res 36:236–245PubMedCrossRef Yang CM, Kandaswamy V, Young D, Sen S (1997) Changes in collagen phenotypes during progression and regression of cardiac hypertrophy. Cardiovasc Res 36:236–245PubMedCrossRef
7.
Zurück zum Zitat Brilla CG, Janicki JS, Weber KT (1991) Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 69:107–115PubMedCrossRef Brilla CG, Janicki JS, Weber KT (1991) Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 69:107–115PubMedCrossRef
8.
Zurück zum Zitat Brooks WW, Bing OH, Robinson KG et al (1997) Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 96:4002–4010PubMedCrossRef Brooks WW, Bing OH, Robinson KG et al (1997) Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 96:4002–4010PubMedCrossRef
9.
Zurück zum Zitat Brilla CG, Pick R, Tan LB et al (1990) Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67:1355–1364PubMedCrossRef Brilla CG, Pick R, Tan LB et al (1990) Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67:1355–1364PubMedCrossRef
10.
Zurück zum Zitat Brilla CG, Matsubara LS, Weber KT (1993) Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 71:12A–16APubMedCrossRef Brilla CG, Matsubara LS, Weber KT (1993) Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 71:12A–16APubMedCrossRef
11.
Zurück zum Zitat Mancia G, Grassi G, Giannattasio C, Seravalle G (1999) Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 34:724–728PubMedCrossRef Mancia G, Grassi G, Giannattasio C, Seravalle G (1999) Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 34:724–728PubMedCrossRef
12.
Zurück zum Zitat Pimenta E, Oparil S (2012) Renal sympathetic denervation for treatment of hypertension. Curr Treat Options Cardiovasc Med in press Pimenta E, Oparil S (2012) Renal sympathetic denervation for treatment of hypertension. Curr Treat Options Cardiovasc Med in press
13.
Zurück zum Zitat Brandt MC, Mahfoud F, Reda S et al (2012) Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 59:901–909PubMedCrossRef Brandt MC, Mahfoud F, Reda S et al (2012) Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 59:901–909PubMedCrossRef
14.
Zurück zum Zitat Bombelli M, Facchetti R, Carugo S et al (2009) Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens 27:2458–2464PubMedCrossRef Bombelli M, Facchetti R, Carugo S et al (2009) Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens 27:2458–2464PubMedCrossRef
15.
Zurück zum Zitat Franklin SS, Wachtell K, Papademetriou V et al (2005) Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a life substudy. Hypertension 46:492–499PubMedCrossRef Franklin SS, Wachtell K, Papademetriou V et al (2005) Cardiovascular morbidity and mortality in hypertensive patients with lower versus higher risk: a life substudy. Hypertension 46:492–499PubMedCrossRef
16.
Zurück zum Zitat Asai K, Yang GP, Geng YJ et al (1999) Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G (salpha) mouse. J Clin Invest 104:551–558PubMedCentralPubMedCrossRef Asai K, Yang GP, Geng YJ et al (1999) Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G (salpha) mouse. J Clin Invest 104:551–558PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Krum H, Schlaich M, Whitbourn R et al (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373:1275–1281PubMedCrossRef Krum H, Schlaich M, Whitbourn R et al (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373:1275–1281PubMedCrossRef
18.
Zurück zum Zitat Perlini S, Palladini G, Ferrero I et al (2005) Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension 46:1213–1218PubMedCrossRef Perlini S, Palladini G, Ferrero I et al (2005) Sympathectomy or doxazosin, but not propranolol, blunt myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension 46:1213–1218PubMedCrossRef
19.
Zurück zum Zitat Levick SP, Murray DB, Janicki JS, Brower GL (2010) Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart. Hypertension 55:270–276PubMedCentralPubMedCrossRef Levick SP, Murray DB, Janicki JS, Brower GL (2010) Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart. Hypertension 55:270–276PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Schlaich MP, Sobotka PA, Krum H et al (2009) Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 361:932–934PubMedCrossRef Schlaich MP, Sobotka PA, Krum H et al (2009) Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 361:932–934PubMedCrossRef
21.
Zurück zum Zitat DiBona GF (2004) The sympathetic nervous system and hypertension: recent developments. Hypertension 43:147–150PubMedCrossRef DiBona GF (2004) The sympathetic nervous system and hypertension: recent developments. Hypertension 43:147–150PubMedCrossRef
22.
Zurück zum Zitat Wyss JM, Oparil S, Sripairojthikoon W (1992) Neuronal control of the kidney: contribution to hypertension. Can J Physiol Pharmacol 70:759–770PubMedCrossRef Wyss JM, Oparil S, Sripairojthikoon W (1992) Neuronal control of the kidney: contribution to hypertension. Can J Physiol Pharmacol 70:759–770PubMedCrossRef
23.
Zurück zum Zitat Brilla CG, Zhou G, Matsubara L, Weber KT (1994) Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26:809–820PubMedCrossRef Brilla CG, Zhou G, Matsubara L, Weber KT (1994) Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26:809–820PubMedCrossRef
24.
Zurück zum Zitat Villarreal FJ, Kim NN, Ungab GD et al (1993) Identification of functional angiotensin ii receptors on rat cardiac fibroblasts. Circulation 88:2849–2861PubMedCrossRef Villarreal FJ, Kim NN, Ungab GD et al (1993) Identification of functional angiotensin ii receptors on rat cardiac fibroblasts. Circulation 88:2849–2861PubMedCrossRef
25.
Zurück zum Zitat Chevalier B, Heudes D, Heymes C et al (1995) Trandolapril decreases prevalence of ventricular ectopic activity in middle-aged SHR. Circulation 92:1947–1953PubMedCrossRef Chevalier B, Heudes D, Heymes C et al (1995) Trandolapril decreases prevalence of ventricular ectopic activity in middle-aged SHR. Circulation 92:1947–1953PubMedCrossRef
26.
Zurück zum Zitat Dias LD, Casali KR, Leguisamo NM et al (2011) Renal denervation in an animal model of diabetes and hypertension: impact on the autonomic nervous system and nephropathy. Cardiovasc Diabetol 10:33PubMedCentralPubMedCrossRef Dias LD, Casali KR, Leguisamo NM et al (2011) Renal denervation in an animal model of diabetes and hypertension: impact on the autonomic nervous system and nephropathy. Cardiovasc Diabetol 10:33PubMedCentralPubMedCrossRef
Metadaten
Titel
Effects of renal sympathetic denervation and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy
Comparison in spontaneously hypertensive rats
verfasst von
X. Ding
X. Xu
Y. Yan
X. Song
S. Liu
G. Wang
D. Su
Q. Jing
Y. Qin
Publikationsdatum
01.06.2015
Verlag
Urban & Vogel
Erschienen in
Herz / Ausgabe 4/2015
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-014-4110-5

Weitere Artikel der Ausgabe 4/2015

Herz 4/2015 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.